<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02772588</url>
  </required_header>
  <id_info>
    <org_study_id>15-334</org_study_id>
    <secondary_id>c15-164</secondary_id>
    <nct_id>NCT02772588</nct_id>
  </id_info>
  <brief_title>AASUR in High Risk Prostate Cancer</brief_title>
  <official_title>ARN-509+Abiraterone Acetate+Leuprolide With Stereotactic, Ultra-Hypofractionated Radiation (AASUR) in Very High Risk Prostate Cancer: A Single Arm, Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether anti-testosterone medications, when
      administered before, during, and after high-dose, precision radiation, will be effective in
      preventing the prostate cancer from returning.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>proportion of patients with biochemical failure</measure>
    <time_frame>36 months</time_frame>
    <description>Biochemical failure is defined as an increase in PSA by more than 2ng/mL above the nadir value. PSA rise equals or exceeds 2ng/mL will be the date of failure.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>patients with prostate cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients will receive a total of 6 months of leuprolide, abiraterone, and ARN-509 to begin three months prior to RT and continuing until approximately 3 months post-RT. Patients will be assessed every 4 weeks (±1 week) (a cycle = 28 days) throughout their treatment with the study drugs, and at least once during RT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARN-509</intervention_name>
    <arm_group_label>patients with prostate cancer</arm_group_label>
    <other_name>apalutamide</other_name>
    <other_name>JNJ-56021927</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone</intervention_name>
    <arm_group_label>patients with prostate cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuprolide</intervention_name>
    <arm_group_label>patients with prostate cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>stereotactic, ultra-fractionated radiotherapy</intervention_name>
    <arm_group_label>patients with prostate cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological or cytologic evidence of adenocarcinoma of the prostate confirmed at
             local institution.

          -  At least one of the following:

          -  Two or more high risk features OR

          -  Gleason score 8-10

          -  PSA ≥20 ng/mL within two months prior to registration

          -  Clinical Stage ≥T3 disease, as determined by standard digital rectal examination (DRE)

          -  Radiographic stage ≥T3 disease as determined by a ≥75% probability of extracapsular
             extension or seminal vesicle invasion per reading radiologist

          -  Any Gleason 9 or 10 disease OR &gt;4 cores of Gleason 8 disease

          -  KPS ≥ 70%

          -  IPSS (International Prostate Symptom Score) ≤ 20F

          -  Patient must be available for follow-up

          -  Laboratory test findings within 28 days of study registration :

          -  Adequate hepatic function:

          -  Bilirubin ≤ 1.5 times the upper institutional limits of normal (ULN). Patients with a
             history of Gilbert's syndrome may be enrolled if the total bilirubin is &lt; 3 mg/dL with
             a predominance of indirect bilirubin. If the total bilirubin is &gt;1.5 x the
             institutional ULN, direct and indirect bilirubin will be measured and if direct
             bilirubin is ≤ 1.5 x the institutional ULN, the patient will be eligible to
             participate

          -  SGPT (ALT) and SGOT (AST) ≤ 2.5 x ULN

          -  Adequate renal function with creatinine &lt;2.0 x the institutional ULN

          -  Adequate hematologic function:

          -  Absolute neutrophil counts ≥ 1500 cell/mm3

          -  Platelets ≥ 100,000 cells/mm3 (independent of blood transfusion and/or growth factors
             within 3 months prior to registration)

          -  Hemoglobin value ≥9 g/dL at the Screening Visit (independent of blood transfusion
             and/or growth factors within 3 months prior to registration)

          -  Albumin ≥ 3.0 g/dL

          -  Potassium ≥ 3.5 mmol/L

          -  Patients with pelvic and/or retroperitoneal lymph nodes &lt; 1.5 cm in short axis are
             eligible as they are not considered to have definitive metastases

          -  Willing and able to provide written informed consent and HIPAA authorization for the
             release of personal health information NOTE: HIPAA authorization may be either
             included in the informed consent or obtained separately

          -  Males 18 years of age and above

          -  The effects of apalutamide, abiraterone, leuprolide and stereotactic,
             ultra-hypofractionated radiation on the developing human fetus at the recommended
             therapeutic dose are unknown. Men (including men with vasectomies) must agree to use
             adequate contraception (a condom and another effective method of birth control) prior
             to registration, for the duration of study participation, and for at least 3 months
             thereafter. Men must also agree not to donate sperm for the duration of study
             participation, and for at least 3 months thereafter.

        Exclusion Criteria:

          -  Radiographic evidence of metastatic disease

          -  Patients with one or more positive lymph nodes as determined by radiographic
             assessment of MRI or CT NOTE: lymph nodes noted on MRI or CT to be &gt; 1.5 cm on the
             short axis will require review by the local reference radiologist per institutional
             RECIST review practices. If the lymph nodes are considered suspicious on repeat
             review, they must be confirmed negative for study participation

          -  Prior treatment for prostate cancer; this includes any prior surgery (including TURP),
             chemotherapy, radiation, or anti-androgen therapy.

          -  Prior use of steroidal antiandrogens (megestrol acetate, cyproterone acetate), AR
             partial agonists, ketoconazole, chemotherapy, immunotherapy, estrogens,
             radiopharmaceuticals within 3 months before registration and during administration of
             study treatment

          -  Prior use of non-steroidal anti-androgens (e.g., bicalutamide, flutamide, nilutamide)
             within 1 month before registration

          -  Prior treatment with medications known to lower the seizure threshold within 4 weeks
             of registration (see section 5.5.2 apalutamide for a list of prohibited medications)

          -  History of another malignancy within the previous 3 years except for the following:
             adequately treated basal cell or squamous cell skin cancer, superficial bladder
             cancer, adequately treated Stage I or Stage II cancer currently in complete remission,
             or any other cancer that has been in complete remission for at least 3 years

          -  Severe hepatic impairment (Child-Pugh Class C)

          -  Concurrent treatment with strong CYP3A4 inducers (e.g., phenytoin, carbamazepine,
             rifampin, rifabutin, rifapentine, phenobarbital)

          -  Major surgery within 4 weeks of registration

          -  Presence of a pacemaker

          -  Active infection or other medical condition that would make prednisone use
             contraindicated

          -  A known hypersensitivity to abiraterone acetate, apalutamide, and prednisone and/or
             any of their excipients

          -  Severe or unstable angina, myocardial infarction, symptomatic congestive heart
             failure, arterial or venous thromboembolic events (e.g., pulmonary embolism,
             cerebrovascular accident including transient ischemic attacks), or clinically
             significant ventricular arrhythmias within 6 months prior to registration.

          -  Seizure or known condition that may pre-dispose to seizure (including but not limited
             to prior stroke, transient ischemic attack, loss of consciousness within 1 year prior
             to randomization, brain arteriovenous malformation; or intracranial masses such as
             schwannomas and meningiomas that are causing edema or mass effect)

          -  Any ECG changes that interfere with QT interval interpretation (e.g., left bundle
             branch block, frequent premature ventricular contractions)

          -  Prolonged QTc &gt;450ms at the Screening Visit

          -  Uncontrolled diabetes, heart disease, hypertension

          -  Gastrointestinal disorder affecting absorption

          -  Active symptomatic viral hepatitis or chronic liver disease

          -  History of pituitary or adrenal dysfunction

          -  Active Infection (e.g., human immunodeficiency virus [HIV] or viral hepatitis) or
             other medical condition that would make prednisone/prednisolone corticosteroid) use
             contraindicated

          -  Patients with Crohn's disease or ulcerative colitis

          -  Patients that cannot tolerate MRI

          -  Inability to have fiducial markers placed

          -  Any condition that in the opinion of the investigator, would preclude participation in
             this study

          -  Enrollment concurrently in another investigational drug study or within 4 weeks of
             registration

          -  Concurrent treatment with strong CYP3A4 inducers (e.g., phenytoin, carbamazepine,
             rifampin, rifabutin, rifapentine, phenobarbital)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sean M McBride, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sean M McBride, MD, MPH</last_name>
    <phone>212-639-5717</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Zelefsky, MD</last_name>
    <phone>212-639-6802</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>John Hopkins Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Curtiland Deville, MD</last_name>
      <phone>202-537-4787</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Spratt, MD</last_name>
      <phone>734-936-4300</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sean M McBride, MD, MPH</last_name>
      <phone>212-639-5717</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sean M McBride, MD,MPH</last_name>
      <phone>212-639-5717</phone>
    </contact>
    <contact_backup>
      <last_name>Michael Zelefsky,, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Sean M McBride, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Molina, MD</last_name>
      <phone>646-962-2072</phone>
    </contact>
    <investigator>
      <last_name>Ana Molina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Den, MD</last_name>
      <phone>215-955-6702</phone>
    </contact>
    <investigator>
      <last_name>Robert Den, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mskcc.org/</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2016</study_first_submitted>
  <study_first_submitted_qc>May 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2016</study_first_posted>
  <last_update_submitted>February 9, 2018</last_update_submitted>
  <last_update_submitted_qc>February 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ARN-509</keyword>
  <keyword>Abiraterone</keyword>
  <keyword>Leuprolide</keyword>
  <keyword>Intensity-Modulated and Image-Guided Radiation Therapy</keyword>
  <keyword>15-334</keyword>
  <keyword>apalutamide,</keyword>
  <keyword>JNJ-56021927</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leuprolide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

